Novavax reports large quarterly revenue declines, rethinks its strategic direction [Yahoo! Finance Canada]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance Canada
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland, said during its earnings report that it would move from developing products to instead partnering with larger pharmaceutical companies and licensing its drug technology. Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for the full year 2024, compared to $984 million the previous year. The sharp decline reflected slumping sales of its COVID-19 vaccine — similar to other vaccine makers. Sales figures also reflected revenues of $200 million from the sale of a manufacturing facility in the Czech Republic to Novo Nordisk (NVO) Wall Street expected $84 million in revenues for the quarter and a loss per share of $0.75 for the quarter. The company reported a loss of $0.51 for the quarter, beating estimates, and loss of $1.23 per
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer leads COVID-19 vaccine peers lower after revamped guidance [Seeking Alpha]Seeking Alpha
- New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use [Yahoo! Finance]Yahoo! Finance
- Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novavax, Inc. (NVAX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 12/15/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- NVAX's page on the SEC website